Takeo Kosaka

Takeo Kosaka

Auto-generated profile, based on publicly available information

Takeo Kosaka

Department of Urology Keio University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
YYYota Yasumizu
Yota Yasumizu
HRHasan Rajabi
Hasan Rajabi
CJCaining Jin
Caining Jin
THTsuyoshi Hata
Tsuyoshi Hata
SPSean Pitroda
Sean Pitroda
DKDonald Kufe
Donald Kufe
Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. Here, we demonstrate that upregulation of MUC1-C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and induces the neural BRN2 transcription factor. MUC1-C activates a MYC→BRN2 pathway in association with induction of MYCN, EZH2 and NE differentiation markers (ASCL1, AURKA and SYP) linked to NEPC progression. Moreover, MUC1-C suppresses the p53 pathway, induces the Yamanaka pluripotency factors (OCT4, SOX2, KLF4 and MYC) and drives stemness. Targeting MUC1-C decreases PC self-renewal capacity and tumorigenicity, suggesting a potential therapeutic approach for CRPC and NEPC. In PC tissues, MUC1 expression associates with suppression of AR signaling and increases in BRN2 expression and NEPC score. These results highlight MUC1-C as a master effector of lineage plasticity driving progression to NEPC.

4 February 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
KOKoichiro Ogihara
Koichiro Ogihara
EKEiji Kikuchi
Eiji Kikuchi
SOShogo Okazaki
Shogo Okazaki
EKEiji Kikuchi
Eiji Kikuchi
TTToshikazu Takeda
Toshikazu Takeda
MOMototsugu Oya
Mototsugu Oya
The prognostic role of CD44v9, a variant isoform of CD44 and a new cell surface marker of cancer stem cells, remains unclear in bladder cancer (BC) patients. Furthermore, limited information is available on the functional role of sulfasalazine (SSZ), which could modulate the CD44v9‐xCT system in order to enhance cisplatin (CDDP)‐induced cytotoxicity and inhibit the metastatic potential of BC. CD44v9 protein expression was examined immunohistochemically in 63 muscle invasive BC (MIBC) patients who underwent radical cystectomy. CD44v9 expression was independently associated with disease recurrence and cancer‐specific death in MIBC. Cytotoxic effects, glutathione levels, and reactive oxygen species production by SSZ and CD44v9 and phospho‐p38MAPK protein expression by SSZ with or without CDDP were assessed in MBT‐2V cells with highly metastatic potential. Sulfasalazine exerted cytotoxic effects against MBT‐2V cells by inhibiting glutathione levels and inducing the production of reactive oxygen species. Sulfasalazine in combination with CDDP appeared to exert strong cytotoxic effects against MBT‐2V cells by inhibiting CD44v9 expression and upregulating phospho‐p38MAPK expression. The inhibitory effects of SSZ with or without CDDP were also investigated using an MBT‐2V lung metastatic model. In the murine lung metastatic BC model, SSZ significantly prolonged animal survival. Furthermore, the combination of SSZ with CDDP exerted stronger inhibitory effects on the establishment of lung tumor nodules than SSZ or CDDP alone. CD44v9 expression could be a clinical biomarker for predicting poor outcomes in MIBC patients. Sulfasalazine in combination with CDDP has potential as a novel therapy against metastatic BC.

12 November 2013 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NTNobuyuki Tanaka
Nobuyuki Tanaka
EKEiji Kikuchi
Eiji Kikuchi
KKKent Kanao
Kent Kanao
KMKazuhiro Matsumoto
Kazuhiro Matsumoto
HKHiroaki Kobayashi
Hiroaki Kobayashi
MOMototsugu Oya
Mototsugu Oya

30 June 2016 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KSKeisuke Shigeta
Keisuke Shigeta
TKTakeo Kosaka
Takeo Kosaka
SKShigehisa Kitano
Shigehisa Kitano
YYYota Yasumizu
Yota Yasumizu
YMYasumasa Miyazaki
Yasumasa Miyazaki
MOMototsugu Oya
Mototsugu Oya

16 April 2013 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
TKT Kosaka
T Kosaka
YMY Miyazaki
Y Miyazaki
AMA Miyajima
A Miyajima
SMS Mikami
S Mikami
YHY Hayashi
Y Hayashi
MOM Oya
M Oya
We recently isolated vasohibin-1 (VASH1), a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells (ECs), and the status of VASH1 expression has been documented in various cancer angiogenesis. The aim of this study was to assess the prognostic value of VASH1 expression in prostate cancer (PCa). In this study, we retrospectively analysed the clinical records and evaluated the VASH1 expression of tumour microvessels in 167 patients with PCa who underwent radical prostatectomy. We immunohistochemically examined the microvessels positive for anti-CD34 as microvessel density (MVD) and the microvessels with activated ECs positive for VASH1 density. We found that the VASH1 expression was restricted to ECs in the tumour stroma. VASH1 density was significantly associated with pathological T stage, Gleason score and MVD. The 5-year PSA recurrence-free survival rate was 58.8% in patients with higher VASH1 density ( ≧ 12 per mm2) and 89.1% in patients with lower VASH1 density (<12 per mm2), respectively (P<0.001). Microvessel density was not an independent predictor of PSA recurrence. Multivariate analysis revealed that high VASH1 density was an independent prognostic indicator of PSA recurrence (P=0.007, HR=2.950). VASH1 density represents a clinically relevant predictor of patient prognosis and can be a new biomarker that would provide additional prognostic information in PCa.

10 July 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
HHHiroshi Hongo
Hiroshi Hongo
TKTakeo Kosaka
Takeo Kosaka
MOMototsugu Oya
Mototsugu Oya
Cabazitaxel (CBZ) is approved for docetaxel‐resistant castration‐resistant prostate cancer (CRPC). However, efficacy of CBZ for CRPC is limited and there are no effective treatments for CBZ‐resistant CRPC. In order to investigate the CBZ‐resistant mechanism, the establishment of a CBZ‐resistant cell line is urgently needed. We established CBZ‐resistant CRPC cell lines DU145CR and PC3CR by incubating DU145 and PC3 cells with gradually increasing concentrations of CBZ for approximately 2 years. We analyzed the gene expression profiles and cell cycle changes using microarray and flow cytometry. Pathway analysis revealed DU145CR cells had enhanced gene clusters of cell division and mitotic nuclear division. Enhancement of ERK signaling was detected in DU145CR cells. DU145CR cells had resistance to G2/M arrest induced by CBZ through ERK signaling activation. The MEK inhibitor PD184352 significantly inhibited cell proliferation of DU145CR. In contrast to DU145CR, PC3CR cells had enhancement of PI3K/AKT signaling. The PI3K/mTOR inhibitor NVP‐BEZ 235 had a significant antitumor effect in PC3CR cells. Cabazitaxel ‐resistant CRPC cells established in our laboratory had enhancement of cell cycle progression signals and resistance to G2/M arrest induced by CBZ. Enhancement of ERK signaling or PI3K/AKT signaling were detected in the cell lines, so ERK or PI3K/AKT could be therapeutic targets for CBZ‐resistant CRPC.